BMC Pharmacology



Poster presentation

Open Access

Regulation of soluble guanylyl cyclase by phosphorylation

Zongmin Zhou¹, Nazish Sayed², Anastasia Pyriochou³, David Fulton⁴, Annie Beuve² and Andreas Papapetropoulos*³

Address: ¹"G.P. Livanos" Lab, Dept of Critical Care, University of Athens, Greece, ²Dept of Pharmacology and Physiology, UMDNJ, New Jersey, USA, ³Lab of Molecular Pharmacology, Dept of Pharmacy, University of Patras, Greece and ⁴Vascular Biology Center, Medical College of Georgia, USA

Email: Andreas Papapetropoulos* - apapapet@upatras.gr

* Corresponding author

from 4th International Conference of cGMP Generators, Effectors and Therapeutic Implications Regensburg, Germany. 19–21 June 2009

Published: 11 August 2009

BMC Pharmacology 2009, 9(Suppl 1):P80 doi:10.1186/1471-2210-9-S1-P80

This abstract is available from: http://www.biomedcentral.com/1471-2210/9/S1/P80

© 2009 Zhou et al; licensee BioMed Central Ltd.

Background

Soluble guanylyl cyclase (sGC) is a receptor for the signaling molecule nitric oxide (NO). Binding of NO to the sGC heme moiety leads to increased cGMP synthesis and activation of cGMP-dependent protein kinase (PKG). As sGC subunits contain putative phosphorylation sites for PKG, we tested whether sGC activity is regulated by PKG.

Results

In vitro kinase assays revealed that the $\alpha 1$, but not the $\beta 1$, subunit of sGC is a PKG substrate and that the phosphorvlation site is located within the first 360 residues of the α1. A constitutively active form of PKG stimulated incorporation of ^{32}P into the $\alpha 1$ subunit in vivo. In addition, PKG could be detected in sGC immunoprecipitates, suggesting that the two proteins interact in cells. Serine to alanine mutation of putative PKG sites revealed that Ser64 is the main phosphorylation site for PKG. After generating a phospho-specific antibody for Ser64, we could demonstrate that phosphorylation of endogenous sGC on Ser 64 increases in cells and tissues exposed to NO. Phosphorylation of sGC in cells following SNP stimulation was blocked by the peptide inhibitor of PKG, DT-3. Wild-type (wt) sGC when co-expressed in COS cells with a constitutively active form of PKG exhibited lower basal and NOstimulated cGMP accumulation. In contrast, the S64A α 1/ β1 sGC was resistant to the PKG-induced reduction in activity. Moreover, co-cultures of endothelial cells with smooth muscle expressing a phosphorylation-resistant

form of sGC, exhibited higher levels of cGMP (both basally and following stimulation with bradykinin) compared to co-cultures expressing wild-type sGC. Phosphorylation of the $\alpha 1$ subunit did not alter its ability to form heterodimers with $\beta 1.$ Using purified sGC and mutants, we observed that the S64D $\alpha 1$ phosphomimetic/ $\beta 1$ dimer exhibited lower Vmax; moreover, the decrease in Km after NO stimulation was less pronounced in S64D $\alpha 1/\beta 1$ compared to wt sGC. Expression of a phosphorylation deficient form of sGC showed reduced desensitization to acute NO exposure and allowed for greater VASP phosphorylation.

Conclusion

We conclude that PKG phosphorylates sGC on Ser64 of the $\alpha 1$ subunit and phosphorylation inhibits sGC activity, establishing a negative feedback loop.